Our mission to deliver world-class research and education is being delivered in partnership with the National Health Service (NHS). Barts and The London School of Medicine and Dentistry works closely with Barts and The London NHS Trust, which is currently finalising a tripartite merger with Newham University Hospital and Whipp's Cross University Hospital to form a new NHS Trust for east and north-east London. We are also involved the NHS-led Academic Health Science Centres at University College and King’s College, London.
Through our North East London Health partnership, Barts and The London School of Medicine and Dentistry leads the North East, Central London and Essex (NECLES) Health Innovation and Education Cluster (HIEC), which is a dynamic network of health educators, innovators and health care practitioners. The aim of this network is to transform the health of the public across the region, changing areas of social disadvantage and poor health outcomes to ones of excellence.
Barts and The London School of Medicine and Dentistry has followed a programme of strategic development over a number of years. This has involved a focused programme of recruitment of leading research groups from the UK and abroad. We have also invested more than £100 million in state-of-the-art facilities.
Find out more about the research taking place in each of our six institutes.
Barts Cancer Institute (BCI) along with the Centre for Cancer Prevention in the Wolfson Institute has been designated a Cancer Research UK Centre of Excellence. As well as enhancing cancer research in the UK, the centre trains the clinical and non-clinical researchers of the future. It brings together our top-ranked scientists in the medical school with the expert clinical teams to transform laboratory discoveries into benefits for patients. The Centre will focus particularly on pancreatic cancer, as well as breast, ovarian and prostate cancer, leukaemia and lymphoma. The laboratory programme explores the genes that drive cancer, aiming to identify markers for early diagnosis and targets for new therapies. The BCI is also a major participant in London Cancer which brings together research expertise from Barts and The London School of Medicine and Dentistry as well as University College, London. The BCI is at the forefront in cancer gene therapy and stem cell approaches, with a wide-ranging programme of clinical trials of experimental agents.
The Blizard Institute of Cell and Molecular Science (BICMS) facilitates research in genomic medicine, cell biology and tissue engineering, infection and immunology and neurosciences, with an annual research grant expenditure of more than £16m. It hosts a cross-disciplinary initiative in stem cell biology, a research consortium which involves many institutes across the College. It is also home to the Health Protection Agency’s Mycobacterium Reference Unit (MRU) that plays a pivotal role in the UK's fight against TB. Together with the Wolfson Institute, the BICMS leads on Public Health initiatives across the School of Medicine and Dentistry.
The Institute of Dentistry, which has just celebrated its centenary (2011), has a long and proud record in the delivery of internationally recognised research in oral and dental sciences. It combines a strong tradition of clinical, epidemiological and public health research in dentistry with a solid basic science research base which brings together a range of multi-disciplinary teams with complementary skills from clinical science, cell and molecular biology, microbiology, material science and biophysics. Research is organised within the four main thematically linked research groups of Immune and Inflammatory Disease; Caries, Hard Tissue and Materials Research; Population Studies and Oral Cancer. The Institute has access to an array of superb modern research and clinical facilities, and has a wide range of national and international collaborative links.
The Institute of Health Sciences Education is the School of Medicine and Dentistry's principal resource for the delivery of education and training, and for innovative research and development in educational methodology. It also houses the highly successful Health Innovation and Education Cluster (HIEC) which has developed a portfolio of inter-disciplinary training opportunities and translational initiatives designed to benefit patient care across North East London and the surrounding region. The HIEC is being developed into an Educational Academy for health professionals.
The William Harvey Research Institute (WHRI) is one of the largest multidisciplinary pharmacological institutes in Europe with a fully integrated clinical and basic science research environment devoted to understanding mechanisms in disease and therapeutic innovation. The Institute has state-of-the-art clinical, pharmacological, genomic, proteomic and imaging technologies used by its researchers across three key areas – cardiovascular, inflammation and endocrine research. Major funders of its research include the Medical Research Council, The Wellcome Trust, The British Heart Foundation, The Gates Foundation, Arthritis Research UK and the EU. The Institute is committed to translating scientific findings into clinical applications and has hosted two consecutive awards for a National Institute for Health Research (NIHR) Cardiovascular Biomedical Research Unit (£12m), an Arthritis Research UK Early Arthritis Treatment Centre, a Medical Research Council MATURA programme for patient stratification, and a Medical Research Council Centre in Electronic Health based around innovative trial designs utilising electronic health records.
The Wolfson Institute of Preventive Medicine is an internationally renowned centre for excellence in epidemiology and preventive medicine. The Institute comprises of the Centre for Environmental and Preventive Medicine (CEPM); the Centre for Cancer Prevention (part of the CRUK Cancer Centre of Excellence) and the Centre for Psychiatry. Groundbreaking work at the Institute includes pioneering work on passive smoking, cancer screening and prevention, screening for neural tube defects and Down’s syndrome and the substantial effects of periconceptual folic acid in the prevention of neural tube defects.